254 related articles for article (PubMed ID: 32538874)
1. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
Isles M
Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
[TBL] [Abstract][Full Text] [Related]
2. Potential risks of pharmacy compounding.
Gudeman J; Jozwiakowski M; Chollet J; Randell M
Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
[TBL] [Abstract][Full Text] [Related]
3. [Improving the quality of compounded medicines through self-assessment: proof of concept].
Wauters K; Fierens C; Corthout J; Sarre S; Saevels J
J Pharm Belg; 2014 Jun; (2):26-33. PubMed ID: 25055453
[TBL] [Abstract][Full Text] [Related]
4. Applying Quality by Design Concepts to Pharmacy Compounding.
Timko RJ
Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
[TBL] [Abstract][Full Text] [Related]
5. Compounded medicines and 'off label' prescribing - a case for more guidance.
Fois RA; Mewes BT; McLachlan AJ; Ramzan I
Aust Fam Physician; 2009; 38(1-2):16-20. PubMed ID: 19283230
[TBL] [Abstract][Full Text] [Related]
6. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
[TBL] [Abstract][Full Text] [Related]
7. Safe practices for compounding of parenteral nutrition.
Cohen MR
JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):14S-19S. PubMed ID: 22383681
[TBL] [Abstract][Full Text] [Related]
8. Patient safety incident reports related to traditional Japanese Kampo medicines: medication errors and adverse drug events in a university hospital for a ten-year period.
Shimada Y; Fujimoto M; Nogami T; Watari H; Kitahara H; Misawa H; Kimbara Y
BMC Complement Altern Med; 2017 Dec; 17(1):547. PubMed ID: 29268743
[TBL] [Abstract][Full Text] [Related]
9. Council of Europe Resolution CM/Res(2016)2: a major contribution to patient safety from reconstituted injectable medicines?
Beaney AM; Le Brun P; Ravera S; Scheepers H
Eur J Hosp Pharm; 2020 Jul; 27(4):216-221. PubMed ID: 32587080
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy compounding of high-risk level products and patient safety.
Mullarkey T
Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
[TBL] [Abstract][Full Text] [Related]
11. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
Brion F; Nunn AJ; Rieutord A
Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
[TBL] [Abstract][Full Text] [Related]
12. Quality, safety and efficacy in the 'off-label' use of medicines.
Kairuz TE; Gargiulo D; Bunt C; Garg S
Curr Drug Saf; 2007 Jan; 2(1):89-95. PubMed ID: 18690954
[TBL] [Abstract][Full Text] [Related]
13. Issues surrounding compounding of parenteral nutrition.
Robinson LA
JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):36S-37S. PubMed ID: 22275324
[No Abstract] [Full Text] [Related]
14. Frequency, nature and determinants of pharmacy compounded medicines in Dutch community pharmacies.
Buurma H; de Smet PA; van den Hoff OP; Sysling H; Storimans M; Egberts AC
Pharm World Sci; 2003 Dec; 25(6):280-7. PubMed ID: 14689817
[TBL] [Abstract][Full Text] [Related]
15. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
Conroy S
Acta Paediatr; 2003 Apr; 92(4):408-10. PubMed ID: 12801103
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations for the safety preparation of sterile medicines in medical wards].
Martín de Rosales Cabrera AM; López Cabezas C; Pernía López MS; Dávila Pousa C; Vila Clérigues MN; Alonso Herreros JM; García Salom P; Lozano Blázquez A
Farm Hosp; 2014 Jan; 38(1):57-64. PubMed ID: 24483861
[TBL] [Abstract][Full Text] [Related]
17. Time to review how injectable medicines are prepared and administered in European hospitals.
Cousins DH; Otero MJ; Schmitt É
Farm Hosp; 2021 May; 45(4):204-209. PubMed ID: 34218767
[TBL] [Abstract][Full Text] [Related]
18. Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.
de Wilde S; de Jong MGH; Le Brun PPH; Guchelaar HJ; Schimmel KJM
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):3-8. PubMed ID: 29047193
[TBL] [Abstract][Full Text] [Related]
19. Compounded medication for patients with rare diseases.
Dooms M; Carvalho M
Orphanet J Rare Dis; 2018 Jan; 13(1):1. PubMed ID: 29301541
[TBL] [Abstract][Full Text] [Related]
20. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
Minghetti P; Pantano D; Gennari CG; Casiraghi A
Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
